Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-11

Clinical Trial Update: Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of dapagliflozin as part of triple therapy for type 2 diabetes, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FARXIGA (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2016-04-11